Clinical assessment of immune-related adverse events.

about

Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer Inflammatory Arthritis Induced by Pembrolizumab in a Patient With Head and Neck Squamous Cell Carcinoma Immune-related adverse events of immune checkpoint inhibitors: a brief review

P2860

Q57483931-BD89F7DC-329B-489A-8017-AB4DFFB60BB1 Q57491552-D5E57F37-3A88-4D8D-9313-EAA02DB51CD9 Q59126189-E9EB30C6-3136-45E9-9EF8-6D86D474ED8E

P2860

Clinical assessment of immune-related adverse events.

Item

http://www.wikidata.org/entity/Q55292659

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Clinical assessment of immune-related adverse events.

@en

Clinical assessment of immune-related adverse events.

@nl

type

Item

label

Clinical assessment of immune-related adverse events.

@en

Clinical assessment of immune-related adverse events.

@nl

prefLabel

Clinical assessment of immune-related adverse events.

@en

Clinical assessment of immune-related adverse events.

@nl

P1476

Clinical assessment of immune-related adverse events.

@en

P2093

Aaron Sosa

http://www.w3.org/2001/XMLSchema#string

Cristina Simon Olive

http://www.w3.org/2001/XMLSchema#string

Esther Lopez Cadena

http://www.w3.org/2001/XMLSchema#string

Niki Karachaliou

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities

Nivolumab plus ipilimumab in advanced melanoma.

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Pembrolizumab for the treatment of non-small-cell lung cancer

P304

1758835918764628

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1758835918764628

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Rafael Rosell

P577

2018-03-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29623110

http://www.w3.org/2001/XMLSchema#string

P932

5882039

http://www.w3.org/2001/XMLSchema#string

Clinical assessment of immune-related adverse events.

about

P2860

P2860

Clinical assessment of immune-related adverse events.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P932